| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 20 ...

格隆汇12月22日丨万孚生物(300482.SZ)在互动平台表示，万孚生物始终密切跟踪医疗健康领域相关政 策动态，围绕临床诊疗需求与民生健康需求开展产品研发及场景适配工作。在优生优育领域，公司具有 丰富产品线，包括产前的传染病监测、生殖能力检测等产品，可以覆盖绝大多数优生优育需求。公司亦 会根据市场需求动态调整推广及供应策略。 ...

格隆汇12月22日丨万孚生物(300482.SZ)在互动平台表示，万孚生物始终密切跟踪医疗健康领域相关政 策动态，围绕临床诊疗需求与民生健康需求开展产品研发及场景适配工作。在优生优育领域，公司具有 丰富产品线，包括产前的传染病监测、生殖能力检测等产品，可以覆盖绝大多数优生优育需求。公司亦 会根据市场需求动态调整推广及供应策略。 ...

Core Viewpoint - The blood gas analyzer market in China is experiencing a transition from large hospitals to grassroots medical institutions, with a significant increase in procurement in 2023, followed by a decline in 2024 and 2025 due to various factors including medical insurance cost control [1][5][9]. Overview - Blood gas analyzers are high-tech diagnostic instruments used to measure parameters such as pH, PCO2, and PO2 in arterial blood, featuring automated calibration and diagnostics [2][3]. - The market for blood gas analyzers is entering a deep adjustment period, with procurement volumes and values showing significant fluctuations [1][9]. Market Policy - The Chinese government emphasizes the development of the medical device industry, including blood gas analyzers, through various policies aimed at ensuring product quality and patient safety [6][7]. Industry Chain - The upstream of the blood gas analyzer industry includes suppliers of raw materials and core components, while the midstream involves R&D and manufacturing, and the downstream consists of hospitals and healthcare institutions as the primary demand market [7][8]. Current Development - In 2023, the total procurement of blood gas analyzers in China reached 965 units, a year-on-year increase of 22.77%, with a total procurement value of 0.95 billion yuan, up 9.20% [1][9]. - The market is seeing a shift in demand from high-end hospitals to grassroots healthcare facilities, with a notable decline in procurement expected in 2024 and 2025 [1][9]. Competitive Landscape - The market has historically been dominated by foreign brands like Radiometer and Wofun, but domestic companies such as Libang and Kangli are gaining market share, with Libang achieving a market share of 24.28% in 2025 [10][12]. - The overall market share of domestic blood gas analyzers reached 48.44% in 2025, indicating a significant shift towards local production and innovation [10][12]. Future Development Trends - The integration of AI algorithms with blood gas analyzers is expected to enhance diagnostic accuracy and provide preliminary treatment suggestions, while advancements in 5G and IoT will facilitate remote data access and device management [14]. - The trend towards miniaturization and ease of use in portable blood gas analyzers is anticipated to grow, catering to various clinical scenarios [14].

Core Viewpoint - Wanfu Biological (300482.SZ) has received a notification from Shenzhen Youmeili Investment Management Co., Ltd., indicating that as of the market close on December 11, 2025, Youmeili Investment manages a total of 1,230,467 "Wanfu Convertible Bonds," accounting for 20.51% of the total issuance of the company's convertible bonds [1] Group 1 - The total number of "Wanfu Convertible Bonds" held by Youmeili Investment is 1,230,467 [1] - Youmeili Investment's holdings represent 20.51% of the total issuance of the company's convertible bonds [1]

Core Viewpoint - Wanfu Biological (300482.SZ) has received a notification from Shenzhen Youmeili Investment Management Co., Ltd., indicating that as of the market close on December 11, 2025, Youmeili Investment's securities investment funds hold a total of 1,230,467 "Wanfu Convertible Bonds," accounting for 20.51% of the total issuance of the company's convertible bonds [1] Summary by Category - **Company Holdings** - Youmeili Investment holds 1,230,467 convertible bonds of Wanfu Biological [1] - This holding represents 20.51% of the total issuance of Wanfu's convertible bonds [1]

Group 1 - The company announced that the board has agreed to adjust the period for the downward revision of the conversion price of "Wanfang Convertible Bonds" from "October 22, 2025, to January 21, 2026" to "October 22, 2025, to December 8, 2025" [2] - The next period for triggering the downward revision of the conversion price is expected to restart from December 9, 2025 [2] - If the conditions for the downward revision of the conversion price are triggered again, the company will follow relevant procedures to decide whether to exercise the right to downwardly revise the conversion price of "Wanfang Convertible Bonds" [2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-074 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 特别提示： 关于调整不向下修正"万孚转债"转股价格期限的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司董事会同意将不向下修正"万孚转债"转股价格的期限由"2025 年 10 月 22 日至 2026 年 1 月 21 日"调整为"2025 年 10 月 22 日至 2025 年 12 月 8 日"。 下一触发转股价格修正条件的期间从 2025 年 12 月 9 日重新起算，若再次触发"万 孚转债"转股价格向下修正条款，届时公司将按照相关规定履行审议程序，决定 是否行使"万孚转债"转股价格的向下修正权利。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 12 月 8 日 召开了第五届董事会第十八次会议，审议通过了《关于调整不向下修正"万孚转 债"转股价格期限的议案》，具体情况如下： 一、可转换公司债券基本情况 经中国证券监督管理委员会"证监许可[2 ...

广州万孚生物技术股份有限公司 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 第五届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第十八次会议于 2025 年 12 月 8 日下午 15:00 在公司会议室以通讯的方 式召开，因情况紧急，为保证董事会工作的顺利衔接和平稳运行，公司第五届 董事会第十八次会议(以下简称"本次会议")经全体董事一致同意豁免会议通 知时限要求，会议通知于同日以电话、口头等方式送达全体董事。会议应到董 事 7 名，实到 7 名，出席会议人数符合《公司法》和《公司章程》规定。会议 由公司董事长王继华女士主持。 鉴于目前公司二级市场股价表现，并综合考虑未来经营发展等多方面因素， 为维护全体投资者的利益，公司董事会同意调整不向下修正"万孚转债"转股 价格的期限，将不向下修正"万孚转债"转股价格的期限由" ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating challenges in the domestic market and the need for operational optimization [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.69 billion yuan, down 22.52% year-on-year, and a net profit attributable to shareholders of 134 million yuan, down 69.32% [1]. - In Q3 2025, the revenue was 445 million yuan, a decrease of 26.66%, with a net loss of 55 million yuan compared to a profit of 80 million yuan in the same period last year [1]. Industry Challenges - The domestic market is facing phase-specific pressures, including: 1. Centralized procurement affecting the pricing of certain medical products [2]. 2. Adjustments in terminal charging policies that may pose risks of price reductions for non-procurement projects [2]. 3. Changes in diagnostic-related groups (DRG) impacting overall testing volumes in hospitals [2]. Company Initiatives - In response to market pressures, the company is actively optimizing its operations by: 1. Strengthening cash flow management [2]. 2. Divesting from less profitable business segments [2]. 3. Implementing operational reforms to enhance efficiency and organizational vitality [2]. 4. Aligning its core product matrix and channel layout with policy directions to capitalize on market opportunities in grassroots testing capabilities [2]. International Expansion - The company’s international business is entering a phase of realization, with steady growth in Q3 2025, driven by: 1. The introduction of new technology platforms and instruments in key markets [3]. 2. Expansion into mid-tier markets through various new business lines [3]. 3. Localizing supply chains and operations, including the establishment of overseas subsidiaries and plans for forward warehouses [3]. - The U.S. subsidiary is focusing on integrating research, production, and sales in the North American toxicology market, with local production capabilities established [3]. Future Growth Prospects - The respiratory business is expected to contribute significantly to revenue growth, with long-term supply agreements signed with major U.S. clients [4]. - Projections for net profit attributable to shareholders for 2025-2027 are 160 million, 330 million, and 400 million yuan, respectively, with corresponding price-to-earnings ratios of 60, 30, and 25 [4].